tiprankstipranks
Trending News
More News >
Oscar Health (OSCR)
NYSE:OSCR
US Market
Advertisement

Oscar Health (OSCR) AI Stock Analysis

Compare
2,055 Followers

Top Page

OSCR

Oscar Health

(NYSE:OSCR)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 4o)
Rating:73Outperform
Price Target:
$19.00
▲(0.16% Upside)
Oscar Health's strong financial performance and positive technical indicators are the primary drivers of its stock score. However, the negative P/E ratio and operational challenges highlighted in the earnings call weigh down the overall score. The company's strategic initiatives and future profitability goals provide a cautiously optimistic outlook.
Positive Factors
Revenue Growth
Strong revenue growth indicates successful market expansion and product adoption, supporting long-term business sustainability.
Membership Increase
Growing membership base enhances revenue potential and market presence, reinforcing Oscar Health's competitive position.
SG&A Efficiency
Improved SG&A efficiency reflects better cost management, contributing to long-term profitability and operational resilience.
Negative Factors
Increased Medical Loss Ratio (MLR)
Rising MLR indicates higher claims costs, which can pressure margins and challenge profitability if not managed effectively.
Operational Losses
Operational losses highlight ongoing financial challenges, potentially impacting cash flow and delaying profitability goals.
Higher Risk Adjustment Payable
Increased risk adjustment payable can strain financial resources, affecting cash management and financial stability.

Oscar Health (OSCR) vs. SPDR S&P 500 ETF (SPY)

Oscar Health Business Overview & Revenue Model

Company DescriptionOscar Health (OSCR) is a health insurance company focused on providing innovative, technology-driven health care solutions. Operating primarily in the health insurance sector, Oscar Health aims to simplify the health insurance experience through user-friendly digital platforms and personalized care management. The company offers individual and family health plans, employer-sponsored insurance, and Medicare Advantage plans, emphasizing transparency and accessibility in health care services.
How the Company Makes MoneyOscar Health generates revenue primarily through premiums collected from policyholders who enroll in its health insurance plans. The company earns money by charging monthly premiums to individuals and families for coverage, as well as from employer contributions in the case of group plans. Oscar also receives reimbursement from the federal government for Medicare Advantage members. Additional revenue streams may include ancillary services, such as telehealth offerings, and value-based care arrangements that incentivize Oscar to improve patient health outcomes while managing costs. Key partnerships with health care providers and technology platforms further enhance Oscar's ability to deliver value and potentially increase its earnings.

Oscar Health Earnings Call Summary

Earnings Call Date:Aug 06, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 11, 2025
Earnings Call Sentiment Neutral
Oscar Health's earnings call highlighted significant revenue growth and strategic acquisitions, yet faced challenges with increased MLR, operational losses, and higher risk adjustment payables. The company's efforts to improve SG&A efficiency and expand through strategic partnerships are positive steps, but financial losses and market challenges weigh heavily.
Q2-2025 Updates
Positive Updates
Significant Revenue Growth
Oscar Health reported a total revenue of $2.9 billion for Q2 2025, representing a 29% increase year-over-year, driven by higher membership.
Membership Increase
The company ended the quarter with more than 2 million members, an increase of 28% year-over-year, driven by solid retention and above-market growth during open enrollment.
SG&A Efficiency
Oscar Health reported an improvement in the SG&A ratio by 90 basis points year-over-year to 18.7%, aided by lower exchange fee rates and fixed cost leverage.
Strategic Acquisitions and Partnerships
Oscar Health acquired new assets to enhance its consumer marketplace capabilities and announced a partnership with Hy-Vee to launch a new ICHRA product.
Negative Updates
Increased Medical Loss Ratio (MLR)
The MLR increased 12 points year-over-year to 91.1%, primarily driven by an overall increase in average market morbidity.
Operational Losses
Oscar Health reported a loss from operations of $230 million and an adjusted EBITDA loss of $199 million for Q2 2025.
Higher Risk Adjustment Payable
The risk adjustment payable for 2025 increased by $316 million due to higher ACA marketplace morbidity, impacting the company's financials.
Workforce Reduction
Oscar Health announced a reduction in workforce and administrative costs to manage operational expenses, expected to eliminate approximately $60 million in costs for 2026.
Company Guidance
During the Oscar Health Second Quarter 2025 Earnings Conference Call, the company provided several key metrics and guidance updates for the year. Oscar Health reported a total revenue of $2.9 billion for the second quarter, marking a 29% increase year-over-year. The medical loss ratio (MLR) increased by 12 points year-over-year to 91.1%, attributed to an increase in average market morbidity. The company reported a loss from operations of $230 million and an adjusted EBITDA loss of $199 million. For the first half of the year, earnings from operations were $66 million, and adjusted EBITDA was $129 million. Oscar reaffirmed its 2025 guidance, expecting revenue between $12 billion and $12.2 billion and a loss from operations ranging from $200 million to $300 million. They anticipate a full-year MLR between 86% and 87%. The SG&A expense ratio improved by 90 basis points year-over-year to 18.7%. The company is also taking measures to reduce administrative costs by about $60 million for 2026 and has improved its 2025 SG&A guidance by 50 basis points at the midpoint compared to initial guidance. Looking ahead, Oscar plans to return to profitability in 2026, driven by strategic pricing changes and expense management.

Oscar Health Financial Statement Overview

Summary
Oscar Health shows a strong financial trajectory with significant revenue growth, improved profitability metrics, and robust cash flow generation. The balance sheet is solid with low leverage, although the equity ratio indicates room for improvement.
Income Statement
85
Very Positive
Oscar Health has demonstrated a strong revenue growth trajectory, with a significant increase in total revenue from $4.1 billion in 2022 to $10.08 billion in TTM (Trailing-Twelve-Months) 2025. The gross profit margin remains robust at 100%, indicating efficient cost management. Net profit margin has improved from negative figures to 1.22% in TTM 2025, showing progress towards profitability. EBIT and EBITDA margins have also improved, reflecting better operational efficiency.
Balance Sheet
75
Positive
The company's balance sheet shows a solid equity base, with stockholders' equity rising from negative in 2020 to $1.33 billion in TTM 2025. The debt-to-equity ratio is low at 0.22, indicating conservative leverage. Return on equity has turned positive, reflecting enhanced profitability. However, the equity ratio is at 22.81%, suggesting potential room for improvement in equity financing.
Cash Flow
80
Positive
Oscar Health has shown strong cash flow generation, with free cash flow increasing from negative figures to $1.19 billion in TTM 2025. The free cash flow to net income ratio is healthy, indicating efficient cash management. Operating cash flow to net income ratio is high, demonstrating the company's ability to convert earnings into cash effectively.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue10.08B9.18B5.86B4.13B1.92B589.64M
Gross Profit10.08B9.18B5.86B4.13B1.92B589.64M
EBITDA198.05M89.31M-212.00M-572.17M-551.25M-390.98M
Net Income123.33M25.43M-270.73M-606.27M-572.61M-406.82M
Balance Sheet
Total Assets5.84B4.84B3.60B4.53B3.32B2.27B
Cash, Cash Equivalents and Short-Term Investments2.99B2.15B2.56B2.96B1.69B1.19B
Total Debt299.75M299.56M298.78M298.00M0.00142.49M
Total Liabilities4.51B3.82B2.80B3.63B440.02M3.57B
Stockholders Equity1.33B1.01B803.97M890.38M1.39B-1.30B
Cash Flow
Free Cash Flow1.19B950.30M-297.74M351.34M-207.63M208.71M
Operating Cash Flow1.22B978.19M-272.16M380.35M-181.75M222.73M
Investing Cash Flow-1.26B-1.39B577.19M-226.52M-774.51M-344.71M
Financing Cash Flow45.95M68.39M6.45M301.11M1.24B611.71M

Oscar Health Technical Analysis

Technical Analysis Sentiment
Positive
Last Price18.97
Price Trends
50DMA
16.22
Positive
100DMA
16.17
Positive
200DMA
15.23
Positive
Market Momentum
MACD
0.70
Positive
RSI
54.86
Neutral
STOCH
50.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSCR, the sentiment is Positive. The current price of 18.97 is above the 20-day moving average (MA) of 18.31, above the 50-day MA of 16.22, and above the 200-day MA of 15.23, indicating a bullish trend. The MACD of 0.70 indicates Positive momentum. The RSI at 54.86 is Neutral, neither overbought nor oversold. The STOCH value of 50.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OSCR.

Oscar Health Risk Analysis

Oscar Health disclosed 46 risk factors in its most recent earnings report. Oscar Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Oscar Health Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$4.90B49.61-14.04%48.29%-1436.25%
71
Outperform
9.49B8.6424.55%16.12%10.99%
70
Outperform
15.60B7.857.49%12.96%-23.25%
70
Outperform
30.39B19.398.64%1.40%9.88%-7.25%
63
Neutral
3.28B-60.74-128.23%49.46%66.89%
50
Neutral
1.55B-34.870.00%-4.87%66.16%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
OSCR
Oscar Health
18.97
-3.36
-15.05%
CNC
Centene
31.77
-43.58
-57.84%
HUM
Humana
252.66
-56.00
-18.14%
MOH
Molina Healthcare
175.14
-172.84
-49.67%
CLOV
Clover Health Investments
3.03
0.13
4.48%
ALHC
Alignment Healthcare
17.09
6.11
55.65%

Oscar Health Corporate Events

Business Operations and StrategyFinancial Disclosures
Oscar Health to Reaffirm 2025 Guidance at Conference
Neutral
Sep 3, 2025

Oscar Health, Inc. announced its participation in the 2025 Wells Fargo Healthcare Conference on September 3, 2025. During the event, the company plans to reaffirm its updated full-year 2025 guidance, which was initially shared in its preliminary financial results for the second quarter of 2025. This move is likely to impact the company’s operations by reinforcing its financial outlook and could influence stakeholder confidence.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 29, 2025